Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab, and Aflibercept) for treatment of corneal neovascularization

Tariq Al-Debasi; Abdulkareem Al-Bekairy; Abdulmalik Al-Katheri; Shmeylan Al HarbiMahmoud Mansour  "Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab, and Aflibercept) for treatment of corneal neovascularization”    -Saudi Journal of Ophthalmology (2017) 31, 99–105 |http://dx.doi.org/10.1016/j.sjopt.2017.02.008

 

Please click here to see the article.

Developed by:  EduTech / COP-ITS 2012